Drugs used in obstetrics
August 25, 2019
Pediatric Integrative Medicine
August 25, 2019
FDA Approved Drugs for Dermatology
Drugs Approved in 2019:
Duobrii (halobetasol propionate and tazarotene) ; Ortho Dermatologics; For the treatment of plaque psoriasis , Approved April 2019
Jeuveau (prabotulinumtoxinA-xvfs); Evolus; For the improvement of glabellar lines, Approved February 2019
Skyrizi (risankizumab-rzaa) ; AbbVie; For the treatment of plaque psoriasis, Approved April 2019
Drugs Approved in 2018:
Braftovi (encorafenib) + Mektovi (binimetinib); Array BioPharma; For the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, Approved June 2018
Cimzia (certolizumab pegol) ; UCB; For the treatment of moderate-to-severe plaque psoriasis, Approved May 2018
Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis , Approved March 2018
Keytruda (pembrolizumab); Merck; For the treatment of Merkel cell carcinoma, Approved December 2018
Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals; For the treatment of cutaneous squamous cell carcinoma, Approved September 2018
Nuzyra (omadacycline) ; Paratek Pharmaceuticals; For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, Approved October 2018
Qbrexza (glycopyrronium) ; Dermira; For the treatment of primary axillary hyperhidrosis, Approved June 2018
Rituxan (rituximab); Biogen IDEC, Genentech; For the treatment of Pemphigus Vulgaris , Approved June 2018
Seysara (sarecycline) ; Paratek Pharmaceuticals; For the treatment of moderate to severe acne vulgaris in patients 9 years of age and older., Approved October 2018
Drugs Approved in 2017:
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017
Dupixent (dupilumab); Regeneron Pharmaceuticals; For the treatment of atopic dermatitis, Approved March 2017
Eskata (hydrogen peroxide); Aclaris Therapeutics; For the treatment of seborrheic keratoses, Approved December 2017
Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic graft-versus-host disease, Approved August 2017
Rhofade (oxymetazoline hydrochloride); Allergan; For the treatment of facial erythema associated with rosacea, Approved January 2017
Siliq (brodalumab); Valeant Pharmaceuticals; For the treatment of plaque psoriasis , Approved February 2017
Tremfya (guselkumab); Janssen Biotech; For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017
Xepi (ozenoxacin) ; Medimetriks; For the treatment of impetigo, Approved December 2017
Drugs Approved in 2016:
Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma; For the treatment of actinic keratoses, Approved May 2016
Eucrisa (crisaborole) ointment; Pfizer; For the treatment of atopic dermatitis, Approved December 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Drugs Approved in 2015
Cosentyx (secukinumab); Novartis; For the treatment of plaque psoriasis, Approved January 2015
Cotellic (cobimetinib) ; Genentech; For the treatment of BRAF V600E or V600K melanoma, Approved November 2015
Enstilar (calcipotriene and betamethasone dipropionate); LEO Pharmaceuticals; For the treatment of psoriasis, Approved October 2015
Imlygic (talimogene laherparepvec) ; Amgen; For the treatment of unresectable recurrent melanoma, Approved October 2015
Kybella (deoxycholic acid); Kythera Biopharma; For the treatment of submental fat, Approved April 2015
Odomzo (sonidegib); Novartis; For the treatment of locally advanced basal cell carcinoma, July 2015
Drugs Approved in 2014:
Dalvance (dalbavancin); Durata Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved May 2014
Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals; For the treatment of onychomycosis of the toenails, Approved June 2014
Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014
Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of unresectable or metastatic melanoma, Approved December 2014
Orbactiv (oritavancin); The Medicines Company; For the treatment of acute bacterial skin and skin structure infections, Approved August 2014
Otezla (apremilast); Celgene; For the treatment of moderate to severe plaque psoriasis, Approved September 2014
Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014
Soolantra (ivermectin) cream, 1%; Galderma Labs; For the treatment of inflammatory lesions of rosacea, Approved December 2014
Drugs Approved in 2013:
Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals; For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013
Mekinist (trametinib); GlaxoSmithKline; For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, Approved May of 2013
Mirvaso (brimonidine); Galderma Labs; For the treatment of facial erythema of rosacea, Approved August 2013
Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013
Tafinlar (dabrafenib); GlaxoSmithKline; For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation, Approved May 2013
Valchlor (mechlorethamine) gel; Ceptaris Therapeutics; For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013
Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013
Drugs Approved in 2012:
Erivedge (vismodegib); Genentech; For the treatment of basal cell carcinoma, Approved January 2012
Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of postherpetic neuralgia, Approved June 2012
Picato (ingenol mebutate) gel; LEO Pharma; For the treatment of actinic keratosis, Approved January 2012
Sklice (ivermectin) lotion; Sanofi Pasteur; For the treatment of head lice, Approved February 2012
Drugs Approved in 2011:
Firazyr (icatibant); Shire Pharmaceuticals; For the treatment of acute attacks of hereditary angioedema, Approved August of 2011
Gralise (gabapentin); Abbott Laboratories; For the treatment of postherpetic neuralgia, Approved February 2011
laViv (azficel-T); Fibrocell Science; For the improvement of nasolabial fold wrinkles in adults, Approved June 2011
Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011
Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011
Zelboraf (vemurafenib); Roche; For the treatment of BRAF + melanoma, Approved August of 2011
Drugs Approved in 2010:
Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010
Veltin (clindamycin phosphate and tretinoin); Stiefel; For the treatment of acne vulgaris, Approved July 2010
Zyclara (imiquimod); Graceway; For the treatment of actinic keratoses of the face and scalp, Approved March 2010
Drugs Approved in 2009:
Stelara (ustekinumab); Janssen Biotech; For the treatment of plaque psoriasis, psoriatic arthritis and Crohn’s disease, Approved September 2009
Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009
Drugs Approved in 2007
Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007
Extina (ketoconazole); Stiefel; For the treatment of seborrheic dermatitis, Approved June 2007
Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Drugs Approved in 2006
Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006
Verdeso (desonide); Connetics Corporation; For the treatment of atopic dermatitis, Approved September 2006
Drugs Approved in 2005
Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005
Drugs Approved in 2003
Amevive (alefacept); Biogen IDEC; For moderate to severe chronic plaque psoriasis., Approved January 2003
Finacea (azelaic acid) Gel, 15%; Berlex Laboratories; Gel formulation for the treatment of rosacea., January 2003
Drugs Approved in 2002
Botox Cosmetic (botulinum toxin type A); Allergan; For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002
Drugs Approved in 2001
Elidel; Novartis; Topical cream for the treatment of atopic dermatitis, Approved December 2001
Estrostep (norethindrone acetate and ethinyl estradiol); Pfizer; For the treatment of moderate acne vulgaris, Approved July 2001
Finevin; Berlex Laboratories; Topical cream for the treatment of mild to moderate inflammatory acne vulgaris, Approved May 2001
Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001
Lamisil Solution, 1%; Novartis; Topical treatment for tinea (pityriasis) versicolor, althete’s foot, jock itch, and ringworm, Approved March 2001
Drugs Approved in 2000
Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel); Dermik Laboratories; For the topical treatment of acne vulgaris, Approved November 2000
Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000
Chloraprep (chlorhexidine gluconate); MEDI FLEX HOSP PRODUCTS; For use as a patient preoperative skin preparation, Approved July 2000
Clindamycin phosphate topical gel; Target Research Associates; For once a day treatment of acne vulgaris, Approved November 2000
Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis; For the treatment of athlete’s foot, jock itch and ringworm, Approved March 2000
Protopic (tacrolimus) ointment; Fujisawa Healthcare; For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis, Approved December 2000
Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA); US Army Medical Research, Material Command; To reduce absorption of chemical warfare agents through the skin, Approved February 2000
Drugs Approved in 1999
Lamisil (terbinafine hydrochloride) Dermagel, 1%; Novartis; Treatment for tinea pedis (athlete’s foot), Approved March 1999
Luxiq (betamethasone valerate) Foam; Connetics Corporation; Treatment for dermatoses of scalp, Approved June 1999
Drugs Approved in 1998
Dynabac; Sanofi-aventis; Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998
Lustra; Medicis Pharmaceutical; Treatment for ultraviolet-induced skin discolorations, Approved January 1998
MetroLotion; Galderma Laboratories; Treatment of inflammatory papules and pustules of rosacea, Approved November 1998
Noritate; Dermik Laboratories; Treatment for rosacea, Approved January 1998
Salagen Tablets; MGI Pharma; Treatment for Sjogren’s Syndrome, Approved February 1998
Sulfamylon; Mylan Laboratories; Treatment used to control bacterial infections on excised burn wounds, Approved June 1998
Thalomid; Celgene; Treatment for moderate to severe erythema nodosum leprosum (ENL), Approved July 1998
Drugs Approved in 1997
Avita Gel; Penederm; Treatment for acne, Approved January 1997
Bactroban Cream; SmithKline Beecham; Treatment for secondarily infected traumatic skin lesions, Approved December 1997
Clindamycin Phosphate Topical Solution USP 1%; Morton Grove Pharmaceuticals; Generic equivalent of CLEOCIN Topical Solution 1%, Approved July 1997
Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997
Dermagraft-TC; Advanced Tissue Sciences; Treatment for partial-thickness and severe burns, Approved October 1997
Klaron (sodium sulfacet amide lotion ) Lotion, 10%; Dermik Laboratories; Treatment for adult acne, Approved February 1997
Mentax (1% butenafine HCl cream); Penederm; Treatment for athlete’s foot, Approved December 1997
Mentax (1% butenafine HCl cream); Penederm; Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus), Approved January 1997
Minoxidil Topical Solution 2% for Women; Alpharma; Generic equivalent of Rogaine, Approved April 1997
Omnicef; Warner-Lambert; Treatment against various bacterias, Approved December 1997
Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol); Ortho-McNeil Pharmaceutical; Treatment for acne in women seeking contraception, Approved January 1997
Propecia; Merck; Treatment for male baldness, Approved December 1997
REGRANEX (becaplermin) Gel; RW Johnson; Treatment for diabetic foot ulcers, Approved December 1997
Retin-A Micro (tretinoin gel) microsphere, 0.1%; Advanced Polymer Systems; Treatment for acne, Approved February 1997
Tazorac topical gel; Allergan; Treatment for Psoriasis, Acne Vulgaris, Approved June 1997
Drugs Approved in 1996
Differin (adapalene gel) Gel, 0.1%; Galderma Laboratories; Treatment for acne, Approved June 1996
Iamin; ProCyte; Gel wound dressing, Approved February 1996
Iontocaine; Iomed; Needle-free anesthetic, Approved May 1996
IvyBlock; EnviroDerm Pharmaceuticals; Treatment for poison ivy, poison oak, and poison sumac, Approved September 1996
Drugs Approved in 1995
Renova (tretinoin emollient cream); Johnson & Johnson; Treatment for facial wrinkles, brown spots, and surface roughness associated with chronic sun exposure, Approved December 1995
